Salarius Pharmaceuticals Files 8-K

Ticker: DCOY · Form: 8-K · Filed: Aug 22, 2025 · CIK: 1615219

Sentiment: neutral

Topics: corporate-filing, financial-reporting

Related Tickers: SLRX

TL;DR

Salarius Pharma (SLRX) filed an 8-K on 8/22/25 for routine corporate updates.

AI Summary

Salarius Pharmaceuticals, Inc. filed an 8-K on August 22, 2025, to report other events and financial statements. The company, formerly known as Flex Pharma, Inc. until July 30, 2014, is incorporated in Delaware and has its principal executive offices in Houston, Texas.

Why It Matters

This filing indicates ongoing corporate activities and financial reporting for Salarius Pharmaceuticals, Inc., providing transparency to investors.

Risk Assessment

Risk Level: low — This is a routine filing for corporate events and financial statements, not indicating immediate significant financial or operational changes.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Salarius Pharmaceuticals, Inc.?

The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of August 22, 2025.

When was Salarius Pharmaceuticals, Inc. formerly known by another name?

Salarius Pharmaceuticals, Inc. was formerly known as Flex Pharma, Inc. until July 30, 2014.

In which state is Salarius Pharmaceuticals, Inc. incorporated?

Salarius Pharmaceuticals, Inc. is incorporated in Delaware.

What is the address of Salarius Pharmaceuticals, Inc.'s principal executive offices?

The address of Salarius Pharmaceuticals, Inc.'s principal executive offices is 2450 Holcombe Blvd. Suite X, Houston, TX 77021.

What is the SEC file number for Salarius Pharmaceuticals, Inc.?

The SEC file number for Salarius Pharmaceuticals, Inc. is 001-36812.

Filing Stats: 4,406 words · 18 min read · ~15 pages · Grade level 20 · Accepted 2025-08-22 17:14:48

Key Financial Figures

Filing Documents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This report contains "forward-looking statements" within the meaning of the U.S. federal securities laws, including the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding the plans, strategies and prospects, both business and financial, of Salarius, Decoy and the combined company. These statements are based on the beliefs and assumptions of Salarius' and Decoy's management. Although Salarius and Decoy believe that these plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the parties cannot assure you that they will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events, or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words "believes," "estimates," "expects," "projects," "target," "goal," "forecasts," "may," "will," "potential," "should," "would," "could," "future," "seeks," "plans," "predicts," "propose," "scheduled," "anticipates," "intends," or similar expressions.

Forward-looking statements in this report include, but are not limited to, statements about the following

Forward-looking statements in this report include, but are not limited to, statements about the following: the expected benefits of, and potential value created by, the Merger for the securityholders of Salarius and Decoy; the likelihood of the satisfaction of certain conditions to the completion of the Merger, including the conditions related to a Qualified Financing, whether and when the Merger will be consummated and that Salarius' common stock remains listed on Nasdaq; the effects of the Merger and any financings consummated in connection with the Merger on the ownership percentages of the Decoy's stockholders and Salarius' stockholders in the combined company; Salarius' expectations regarding its ability to regain compliance with the applicable Nasdaq continued listing requirements in the timeframe required by Nasdaq; Salarius' expectations regarding the timing of the combined company's ability to satisfy the Nasdaq initial listing standard and obtain stockholder approval for the conversion of the Preferred Stock into common stock in connection with step two of the Decoy transaction; the plans, strategies and objectives of management for future operations, including the execution of integration plans and the anticipated timing of filings, commencement of preclinical studies or clinical trials and release of data from such studies or trials; plans to develop and commercialize additional products candidates including planned preclinical, clinical, regulatory, commercialization and manufacturing activities; the attraction and retention of highly qualified personnel; the ability to protect and enhance the combined company's products and intellectual property; developments and projections relating to the combined company's competitors or industry; the combined company's financial performance; Salarius' or Decoy's relationships and actions with third parties; Salarius' and the combined company's ability to maintain the listing of its shares of common sto

01 Other Events

Item 8.01 Other Events DECOY'S BUSINESS Overview of Decoy's and the Combined Company's Proposed Business Decoy's proprietary Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology platform ("IMP 3 ACT TM ") represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning ("ML") and artificial intelligence ("AI") tools alongside high- speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. Peptide conjugates are emerging as a major therapeutic drug modality, with the potential to transform multiple therapeutic areas. This innovative class of drugs, exemplified by successful diabetes and weight loss treatments like Ozempic, Wegovy, Mounjaro and ZepBound, combines small -helical peptides with functional moieties to enhance solubility and extend the duration of action. By decreasing the complexity of peptide conjugate development, Decoy aims to establish itself as a leader in this advancing drug class. Decoy's goal is to build a robust portfolio of novel peptide conjugate therapeutics, initially focusing on infectious diseases and oncology. Through this approach, Decoy intends to revolutionize the design, development, and commercialization of peptide conjugate therapeutics, becoming a fully integrated biopharmaceutical company at the forefront of this exciting field. The peptide conjugate drug class is extremely modular and flexible, making it applicable to a wide range of human disease states and medical indications. Decoy expects that its drug candidates may be used both chronically, like current diabetes or weight loss drugs, or acutely, as is typical of antiviral treatments. Decoy is planning to engineer its peptide conjugates to be delivered via a variety of routes that can be optimally matched to the targeted disease state, including intranasal and pulmonary inhalation, extended-release dermal patches, oral, subcutaneous injec

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing